What's new

Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance

Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance

Feb 12, 2025 - 15:58
 0
Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance
Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance
Read More

Tags:

Previous Article

STAT+: Is Trump’s new order a reprieve for biotech?

Next Article

Slideshow: Valentine’s Day introductions to fall in love with

Related Posts

PSUSA/00002163/202407

PSUSA/00002163/202407

Feb 14, 2025  0

Human medicines European public assessment report (EPAR): Spinraza, nusinersen, Date of authorisation: 30/05/2017, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0

Human medicines European public assessment report (EPAR): Lantus, insulin glargine, Date of authorisation: 09/06/2000, Revision: 42, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0